back to authentic cmo home page





SAN DIEGO CLINIC

THE FIRST TRIALS

THE SAN DIEGO STUDY:
An informal human study was undertaken at a facility called the San Diego Clinic in late 1995. It was conducted by Dr. Len Sands, Ph.D. It started with some stated objectives:

THE QUESTIONS TO BE ANSWERED WERE:
1 What are the optimum dosage levels for treating the various types of arthritis with CMO?

2 Are different dosages important relative to the different types of arthritis?

3 What is the lag time between the start of the treatment and the expected relief of symptoms?

4 What percentage of patients respond to the treatment?

5 What factors, if any, contribute to non

The study was conducted with 48 volunteer patients who had (OA) osteoarthritis, (RA) rheumatoid, and (PA) psoriatic arthritis. The group was comprised of 28 females and 20 males ranging from 32 to 82 years of age. All races and all ethnic backgrounds were represented. Age, gender, race and ethnic background appeared to be irrelevant to the results of the program.

CMO was administered orally in the form of 385 mg capsules. The number of capsules and duration of treatment varied for each group. The final protocol will be found later in this study.

At the end of each trial an evaluation was made using three parameters; inflammation, pain and motion, All but four of the subjects in the studies reported 80% to 100% return of articular mobility as well as 70% to 100% decrease in pain. Probably the most interesting finding was that the relief of inflammation frequently resulted in partial correcting of the deformities. In some cases it resulted in complete corrections. At the end of the entire study, only two subjects said they had failed to notice any change. An examination confirmed no changes in the pair. These two non

During the entire study and follow

This was an informal and independent trial at a private medical clinic. It was undertaken by an individual doctor and other professionals without funding from the government or drug companies. Clinical studies such as these point out fruitful directions for future studies.

GROUP 1
Eleven (11) subjects, was comprised of mild to moderately severe osteoarthritis, including one case of reactive psoriatic arthritis. The eleven subjects took two capsules of CMO twice daily for five days and quit. That was the entire treatment.

Nine of the patients reported 20% to 30% improvement in articulation and inflammation and about 40% to 50% relief of arthritic pain within 36 hours. Improvements, in the same nine, continued rapidly for the next 60 hours, reaching 80% to 100% overall relief by the end of four days. The two remaining subjects reported a 70% to 80% improvement by the end of the fourth day, and both of them continued to see improvements over the next week even though they were no longer on the capsules

Half of this entire group experienced a return of some mild arthritic symptoms after about 3 to 5 weeks following the study. All of them were re

The patient with reactive psoriatic arthritis also experienced an almost complete reversal of his arthritis as well as his associated severe psoriatic skin condition which affected about 20% of his total skin area.

GROUP 2
Nine patients (9) with severe rheumatoid arthritis were grouped together for a second study. Four patients in this group required wheelchairs. One of the patients was on crutches because of a hip fusion. The remaining 4 needed walkers or canes. All of them had pain, inflammation and marked deformations of all the joints in the fingers as well as restriction of motion. Five had some permanent lower back flexion as well as back pain. All of the patients in this study had difficulty grasping and manipulation common objects.

The dosage schedule was two 385 mg capsules twice a day for 7 days, then stop for 7 days and then resume for 5 and 1/2 days

Within three days, six in this group reported a 30% to 50% decrease in pain. Three of the six noticed increased joint mobility, and another three subjects reported little change. In 7 days, five of the patients had a 70% to 90% decrease in pain and 70% to 80% improvement in joint mobility. Three reported themselves to be totally free of pain with almost complete return of joint mobility. The joint deformations which were previously severe seemed to show marked improvement. Only one failed to show changes.

After they had been off treatment for a week, roughly half said they had seen further improvements, but most of it was minor. Two of the patients stayed the same. There was no improvement in the individual who had not seen improvement from the start.They were then re

GROUP 3
Group 3 consisted of 14 subjects with severe rheumatoid arthritis. They were given two 385 mg capsules of CMO twice a day for six days and then nothing. After three days, eleven out of this group had 40% to 50% improvement in articulation and inflammation and 40% to 50% improvement in arthritic pain. All improved rapidly over the next four days, approaching 80% to 100% level. The remaining three had 70% to 80% improvement after seven days.

Most of the subjects continued to experience minor improvement during the first week off the treatment. Six patients, however, noticed some minor recurrence three or four weeks after the treatment and were re

GROUP 4
The fourth group organized contained 14 subjects severely crippled with osteoarthritis. They each took two 385 mg capsules of CMO twice a day for seven days, then off seven days, then back on for five and a half days.

At the onset, three of this group were unable to walk and required wheelchairs. The other eleven used walkers, canes or crutches. All of the patients in this group had pain, inflammation and deformations throughout their hands and fingers. Four of the patients had severely limited movement of their backs and lower back pain. Ten had difficulty grasping and holding objects.

Four days later, ten of the patients reported a 30% to 50% improvement in movement and lessening of inflammation. 40% to 50% of their pain was gone. Ten of them continued to see Improvement over the next 3 days. In seven days they were 80% to 100% better. One subject showed no change.

On the 14th day, at the end of their week off treatment, 9 had continued to feel improvements. Four stayed the same and the one who had failed to improve before stayed the same.

They re-started the CMO again for five and a half more days. At the end of the treatment, eleven had 80% to 100% improvement in pain and mobility. Two had 70% to 80% improvement in mobility and 70% to 90% lessening of pain. One patient, the same as before, experienced no relief.

CONCLUSIONS OF THE STUDY

The optimal dosage level appears to be equal for all three types of arthritis:

Osteoarthritis, Rheumatoid and Psoriatic Arthritis. This is evidenced by the gradual return of minor arthritic symptoms in several of those treated with only 16 to 24 capsules, and no regression in those treated with 50 capsules in two series separated by one week without treatment.

Dosage level requirements appear to be equal irrespective of the severity of the subject's condition.

Initial response time for minor improvement appears to vary from two to seven days irrespective of the severity of the subject's condition.

The time for maximum attainable response appears to be from seven to twentyone days, resulting in 70% to 100% overall improvement. (Apart from the study three of the most severely afflicted subjects were treated again after a five week interval resulting in an additional 10% to 20% overall improvement.)

The two non

In addition, it was evident that for many subjects the relief of inflammation resulted in marked improvement in joint deformation.

There were no side effects of the treatment noted by the subjects or the doctors

Some of the patients were not entirely happy with 70% improvement and so were re

There are, in addition to these studies, hundreds of testimonials and success stories. And the success rate in most cases, if you count success as being a substantial improvement in symptoms, is an astonishing 98% and all of this without risk to the patient.

This concludes these studies and their results.

SAN DIEGO CLINIC

MEMORANDUM
Subject: Heart Disease Relative to CMO

There have been no formal studies conducted with respect to the effects of CMO on individuals with heart disease.

However, considering that CMO is a naturally derived nutritional supplement that has shown to help normalize various physiological and immunological body processes in humans, and since it appears to be completely non

On the contrary, we have received interesting reports regarding persons with certain other ailments who have taken CMO for arthritis as recommended by their physicians and other health care professionals;

1 There have been reports on individuals suffering from hypertension (high blood pressure) whose blood pressure has completely normalized or lowered substantially.

2 There have been reports of individuals suffering from hypotension (low blood pressure) whose blood pressure has completely normalized or raised substantially.

3 There have been reports of individuals with high and even extremely high blood sedi-mentation rates whose sed rates have normalized, even in Lupus patients.

4 There have been reports of individuals with cardiac arrhythmia (abnormal heartbeat rhythm) whose arrhythmia has disappeared.

Those reports are not the result of any formal study. They have been noted from comments provided to us by professionals who have been surprised at these secondary benefits of CMO which they have encountered in their patients during the treatment for arthritis. This tendency by CMO to normalize body processes confirms that it functions as an immunomodulator.

It must not be assumed that other patients will enjoy these same secondary benefits. No formal studies have been conducted to confirm that these benefits are repeatable on a consistent basis.

It must be emphasized that any individual with a serious ailment or condition of any sort should consult with and be closely monitored by their relevant health care professional any time that person undertakes any sort of therapeutic or even nutritional program.

January 1997

SAN DIEGO CLINIC

MEMORANDUM

Subject: CMO and Horses

Our very first experience with horses involved a 19

Furthermore tic returned quite comfortably to breeding in the natural way. Needless to say, the owners were overjoyed

Another interesting case involved a 14

More subtle improvements were evident in a case involving another dressage horse that was progressively becoming more and more resistant to a right lead. In this instance the trainer had already experienced great results with CMO for her own neck and shoulder problems, probably the result of being hauled around an arena by 1000 pound animals for so many years. So why not try CMO on the horse as well? Even before finishing the second bottle the horse lost all resistance to the right lead and showed a marked increase in fluidity of motion which is so important in dressage work.

One horse was conclusively diagnosed as suffering from arthritis by xx-ray confirmation as well.

We recently submitted blood samples of a horse undergoing treatment with CMO for the standard analysis required on the show horse circuit in California. Nothing unusual appeared in the analysis.

Administering CMO to horses call sometimes be a problem with finicky caters. Some owners use a ball gun with great success, but some owners prefer to mix the contents of the capsules in with something of which the horse is particularly fond. Some find that applesauce works well. Others like grated carrots and apples. A commercial oat and molasses mixture often works well too. About 20 capsules it day seem to work well for an average size horse.

CMO has been effective an cats, dogs, hamsters, and pot-bellied pigs for arthritis and hip dysplasia as well. Small animals need only one capsule daily. Two capsules daily for each 50 pounds of body weight.

The statements on this web site have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
back to authentic cmo home page